Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ADC Therapeutics SA (ADCT)

ADC Therapeutics sets $86.6M private placement and reworks debt, royalty deal

Mixed Impact 4 of 5 financing Written later

ADC Therapeutics agreed on October 7, 2026 to sell equity in an $86.6 million private placement, with closing expected October 22, 2026. The company also amended its term loan, cutting principal to $50.0 million, and amended its HealthCare Royalty agreement, removing a $150 million change-of-control payment. The filing gives preliminary third-quarter ZYNLONTA net product revenue of about $21.0 million and cash of $189.2 million, and the new share sales and warrant repricing add dilution for existing shareholders.

Key points

  • Private placement of 12,911,347 common shares at $1.42 per share, plus pre-funded warrants for 48,088,653 shares, expected to close October 22, 2026
  • Term loan prepayment of $70.0 million leaves $50.0 million outstanding; minimum liquidity covenant eliminated and a $65.0 million ZYNLONTA sales covenant set for the quarter ending December 31, 2026
  • HCR amendment removes the $150 million change-of-control payment and lets the company buy out royalties for $525 million by December 31, 2029 or $750 million from January 1, 2030
  • Preliminary Q3 2026 ZYNLONTA net product revenue of about $21.0 million; cash and equivalents of $189.2 million as of September 30, 2026

The filing

CompanyADC Therapeutics SA (ADCT)
Form8-K, current report
Filed with the SECOct 13, 2026, 6:26 AM ET
Accession number0000950103-26-015465

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.